Annual Newsletter 2017

Download a copy here. Newsletter_Autumn_2017.pdf

Latest

Denali Announce Positive LRRK2 Trial Results with Advance to Phase 1b Trial

Denali Therapeutics has announced positive clinical results from their LRRK2 inhibitor programme and their advance to a Phase 1b trial in Parkinson’s patients with and without a genetic LRRK2 mutation.
Cure3 2018: Art for Parkinson's

We are delighted that Cure3 is taking place again this year! Over 80 leading artists and architects will create exclusive works which will be sold at this unique selling exhibition...
Cure3 Art Exhibition

From the 26th to the 28th October the Cure3 Exhibition will be open to the public: a unique selling exhibition featuring original works by more than 80 leading international artists, taking place at Bonhams, London in association with Artwise and in support of The Cure Parkinson's Trust
Alison Anderson and The Cyclopaths take to the saddle once again

Alison Anderson and The Cyclopaths will take to the saddle once again this August as they embark on an incredible cycle challenge pedalling from Lands End to John O'Groats in a bid to raise awareness and funds for CPT.

Denali Announce Positive LRRK2 Trial Results with Advance to Phase 1b Trial

Denali Therapeutics has announced positive clinical results from their LRRK2 inhibitor programme and their advance to a Phase 1b trial in Parkinson’s patients with and without a genetic LRRK2 mutation.
Cure3 2018: Art for Parkinson's

We are delighted that Cure3 is taking place again this year! Over 80 leading artists and architects will create exclusive works which will be sold at this unique selling exhibition...
Parkinson’s Movement Awarded Wellcome Public Engagement Fund Grant

The Cure Parkinson's Trust (CPT) is delighted that Parkinson's Movement (PM) has secured a Wellcome Public Engagement Fund grant from The Wellcome Trust which will support the development of audio/visual content on the PM website over the next two years.
Drug Repurposing in Parkinson's

Given the number of failures and the ever-increasing costs and lengthy processes for drug development, our attention continues to be focused on utilising existing compounds approved for other conditions as novel treatments for Parkinson’s...
R S Macdonald Trust Awards Grant for Further Stem Cell Research

The Cure Parkinson’s Trust is delighted that the R S Macdonald Charitable Trust has awarded a grant to co-fund the continuing dopamine replacement stem cell research of Dr Tilo Kunath at the MRC in Edinburgh.
Trial Design for Parkinson's Disease Modification

Helen Matthews, Deputy CEO, attended a recent summit in New York focused specifically on trial design for disease modification organised by The Michael J. Fox Foundation for Parkinson’s Research.
Kyoto Team Begin Cell Replacement Trial In Parkinson's

Professor Jun Takahashi & colleagues at the University of Kyoto Japan have announced that they are to start the world’s first clinical trial of cells derived from induced pluripotent stem cells in people with Parkinsons...
Cell Replacement Therapies for Parkinson's - Dr Tilo Kunath

Dr Tilo Kunath is working with cells derived from people with Parkinson's to understand the underlying causes of the condition; to test drugs that might treat it and to replace those cells which are lost.
Stem Cell Therapies - Research Update

When diagnosed, people with Parkinson’s have often had the disease for years and have lost over half of the dopamine producing cells in their brain. Now scientists are searching for a way to replace these nerve cells.
LRRK2 May Play a Role in Idiopathic Parkinson's

Abnormally increased kinase activity due to mutations in the leucine-rich repeat kinase 2 (LRRK2) gene is the cause of Parkinson’s in about 3 to 4% of people with Parkinson's however researchers have found that independent of any mutations, LRRK2 may also play a role in idiopathic Parkinson's.

Breakthrough in stem cell treatment for Parkinson's

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.
Tom Isaacs

We are devastated to announce that Tom Isaacs, President and Co-founder of The Cure Parkinson’s Trust (CPT) died on Wednesday morning (31st May). Tom’s passing was unexpected and swift.
New Evidence Suggests Parkinson's Might Not Start in The Brain

A new study adds to a raft of new evidence which suggests Parkinson's starts in the gut.
Trials - Repurposed drugs

Our Linked Clinical Trials initiative (LCT) identifies potential new treatments to slow, stop, or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.
Science news

Read the latest Parkinson's science and research news here.
Our story
The NAC Trial - the facts
Apply for Funding
Diabetes Drug Potential Disease-Modifying Therapy

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.
Stem Cell Therapies - Research Update

When diagnosed, people with Parkinson’s have often had the disease for years and have lost over half of the dopamine producing cells in their brain. Now scientists are searching for a way to replace these nerve cells.

Science news

Read the latest Parkinson's science and research news here. Read more

The Annual Review 2018

Our Annual Review 2018 - your online publication here... Read more

Alison Anderson - Fundraiser of the Year 2017

We are delighted that Alison Anderson is the Alex Flynn Award winner of 2017! Following her diagnosis with Parkinson's, Alison was determined to move forward with optimism - so she took on an awesome and inspiring challenge... Read more

Leave a gift in your Will

A donation to The Cure Parkinson's Trust will make a huge difference to our research to slow, stop or even reverse Parkinson's. Read more